

Immune Checkpoint Inhibitor–Related Pneumonitis: Clinical Challenges, Mechanistic Insights, and Future Directions

Niladri Dutta*

Internal Medicine Trainee, Betsi Cadwaladr University Health Board, UK

*Corresponding author: Niladri Dutta, Internal Medicine Trainee Betsi Cadwaladr University Health Board, NHS Wales, UK

ARTICLE INFO

Received: 📅 August 28, 2025

Published: 📅 September 11, 2025

Citation: Niladri Dutta. Immune Checkpoint Inhibitor–Related Pneumonitis: Clinical Challenges, Mechanistic Insights, and Future Directions. Biomed J Sci & Tech Res 63(2)-2025. BJSTR. MS.ID.009862.

ABSTRACT

Keywords: Immune Checkpoint Inhibitors (ICI); Pneumonitis; Immune-Related Adverse Events (irAEs); PD-1 Inhibitors; CTLA-4 Inhibitors; Steroid-Refractory Pneumonitis; T-Cell Mediated Autoimmunity

Introduction

Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, and CTLA-4 have transformed cancer treatment by increasing T cell–mediated anti-tumor immunity and extending survival in a variety of cancer types. However, immune activation leads to the possibility of immune-related adverse events (irAEs). Despite being uncommon, pneumonitis is a serious immune-related toxicity that can be fatal, resulting in respiratory failure, and require treatment termination. It is essential for both oncologists and pulmonologists to understand its epidemiology, pathogenesis, and treatment.

Epidemiology and Risk Factors

The incidence of ICI-related pneumonitis (CIP) depends on the ICI-agent and its respective regimen. PD-1 inhibitors such as nivolumab and pembrolizumab are associated with all-grade pneumonitis in ~2–5% of patients, with grade ≥3 events in ~1% [1,2]. PD-L1 inhibitors carry a slightly lower risk (1–4%), whereas CTLA-4 monotherapy rarely causes pneumonitis (<1%). Combination regimens, particularly PD-1 plus CTLA-4, have the highest risk (6–10% overall; ~1.5%

severe) of CIP [2,3]. Real-world series suggest higher incidences (5–12%), particularly among patients with lung cancer or pre-existing interstitial lung disease [4]. Additional risk factors include prior thoracic radiation, smoking history, and chronic obstructive pulmonary disease.

Pathogenesis

CIP is thought to be a result of T-cell–mediated autoimmune response to ICIs. Shared antigenic targets between tumor cells and type II pneumocytes, and overlapping T-cell receptor clonotypes in tumor and lung tissue, support this hypothesis [5,6]. Histology frequently shows cryptogenic organizing pneumonia (COP), though Non-Specific Interstitial Pneumonia (NSIP), hypersensitivity pneumonitis, diffuse alveolar damage, and granulomatous inflammation are also reported [7]. Cytokine analyses demonstrate elevated IL-6, IL-17A, and granzyme A in severe cases, implicating dysregulated immune signaling [8,9]. Additional contributors may include anti-CD74 autoantibodies, microbiome modulation, and genetic susceptibility (e.g., HLA alleles) [10]. The heterogeneity of radiologic and histologic patterns suggests converging immunopathogenic pathways.

Clinical Presentation and Diagnosis

CIP typically arises weeks to months after ICI initiation but can present late. Symptoms include cough, dyspnea, and fever, though some patients remain asymptomatic (Table 1). HRCT Thorax reveals patterns such as COP, NSIP, hypersensitivity pneumonitis, or

ARDS-like diffuse alveolar damage [7]. Diagnosis is clinical and relies on excluding infection, tumor progression, and radiation pneumonitis. Recommended workup includes HRCT, bronchoalveolar lavage, and, where necessary, tissue biopsy. Multidisciplinary input is strongly recommended.

Table 1: Reported incidence of immune checkpoint inhibitor-related pneumonitis, stratified by therapy type and severity (all-grade vs. grade ≥ 3).

Therapy Type	All-grade pneumonitis (%)	Grade ≥ 3 pneumonitis (%)	Notes
PD-1 inhibitors (e.g., nivolumab, pembrolizumab)	2 - 5%	~1%	Higher risk in NSCLC vs. melanoma
PD-L1 inhibitors (e.g., atezolizumab, durvalumab, avelumab)	1 - 4%	0.4 - 1%	Slightly lower incidence than PD-1
CTLA-4 inhibitor monotherapy (ipilimumab)	<1%	<0.5%	Rare as monotherapy
PD-1/CTLA-4 combination therapy	6 - 10%	~1.5%	Highest risk; up to 10% in NSCLC

Management and Outcomes

Management is guided by CTCAE severity: [1,3]

- **Grade 1 (asymptomatic):** Withhold ICIs, monitor; approximately 30–40% resolve without steroids.
- **Grade 2 (symptomatic):** Discontinue ICIs; initiate oral prednisone 1–2 mg/kg/day. Most respond within 1–2 weeks.
- **Grade ≥ 3 (severe/life-threatening):** Hospitalize; treat with IV methylprednisolone 1–2 mg/kg/day, taper over ≥ 4 –6 weeks. Up to 30% are steroid-refractory.
- **Steroid-refractory:** Consider infliximab, mycophenolate, or IVIG; ~50–60% achieve improvement. [4,5].

Mortality in high-grade CIP ranges from 10–20% [6]. Permanent ICI discontinuation is common in grade ≥ 2 pneumonitis (~80%). Re-challenge may be attempted after full resolution in selected patients, with success rates of 60–70% but recurrence in ~25% [7].

Future Directions

Current gaps include the absence of standardized diagnostic criteria, reliable biomarkers, and evidence-based strategies for steroid-refractory CIP. Long-term pulmonary sequelae remain poorly characterized. Advances in radiomics, AI-based imaging, circulating biomarkers, and large-scale registries may enable earlier detection, improved risk stratification, and targeted therapies.

Conclusion

ICI-related pneumonitis is an uncommon but serious complication of cancer immunotherapy. Early recognition, multidisciplinary evaluation, and timely corticosteroid initiation are critical. Improved

biomarkers and therapeutic strategies for refractory disease are urgently needed. Ongoing translational research will be key to optimizing outcomes while preserving the benefits of immunotherapy.

References

1. Naidoo J, Wang X, Woo KM, Tunc Iyriboz, Darragh Halpenny, et al. (2017) Pneumonitis in patients treated with anti-PD-1/PD-L1 therapy. *J Clin Oncol* 35(7): 709-717.
2. Wang Y, Zhou S, Yang F, Xinyue Qi, Xin Wang, et al. (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: systematic review and meta-analysis. *JAMA Oncol* 5(7): 1008-1019.
3. Khunger M, Rakshit S, Hernandez AV (2017) Immune checkpoint inhibitor-related pneumonitis: a meta-analysis. *Chest* 152(2): 271-281.
4. Suresh K, Voong KR, Shankar B (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint inhibitors. *J Thorac Oncol* 13(12): 1930-1939.
5. Matsuo M, Yasuda Y, Ishihara Y (2021) Identification of a type II pneumocyte-associated antigen in ICI-related pneumonitis. *Immunol Rev* 302(1): 177-192.
6. Delaunay M, Prévot G, Collot S, Laurent Guilleminault, Alain Didier, et al. (2019) Management of pulmonary toxicity associated with immune checkpoint inhibitors. *Eur Respir Rev* 28(153): 190012.
7. Dolladille C, Ederhy S, Sassier M, Jennifer Cautela, Franck Thuny, et al. (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events. *JAMA Oncol* 6(6): 865-871.
8. Nakamura Y, Tanaka R, Asami Y (2020) Serum IL-6 and CRP as biomarkers of immune-related adverse events in nivolumab-treated melanoma. *Clin Cancer Res* 26(1): 172-181.
9. Park JH, Lee SH, Keam B (2023) Immunopathology of checkpoint inhibitor pneumonitis: transcriptomic analysis of BAL fluid. *J Immunother Cancer* 11(1): e005647.
10. Balaji A, Hsu M, Lin CT (2021) Steroid-refractory immune checkpoint inhibitor pneumonitis: incidence, features, and management. *J Immunother Cancer* 9(7): e001731.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2025.63.009862

Niladri Dutta. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>